ESC Premium Access

Questions and answers / Panel discussion

Topic: Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)
Sponsored by National Lipid Association

Congress Session

4 more presentations in this session

Clinical implications for patients at persistent ASCVD risk

Speaker: Doctor J. Saseen (Aurora, US)


Clinical trial updates

Speaker: Doctor C. Ballantyne (Houston, US)


The future of lipid management: new therapies for LDL-C lowering

Speaker: Doctor H. Bays (Louisville, US)


Post-activity quiz and discussion

Speaker: Doctor P. Morris (Charleston, US)


Access the full session

Targeting of PCSK9 with siRNA for LDL-C reduction in a high-risk population

Speakers: Doctor J. Saseen, Doctor C. Ballantyne, Doctor H. Bays, Doctor P. Morris

About the event



31 August - 4 September 2019

Sessions Presentations

Related content

Open Access

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

27 August 2021

ESC Premium Access

Will coronary atherosclerosis be eliminated?

27 August 2021

ESC Premium Access

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

27 August 2021

This platform is supported by

logo Novo Nordisk